Last reviewed · How we verify
NCT03489616: CRAGMOLC
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients
Status unknown
NA
Last updated 5 April 2018
What this trial tests
NA trial testing rhGM-CSF in Carcinoma, Non-Small-Cell Lung in 45 participants. Status unknown.
Timeline
15 January 2018
Primary endpoint
1 July 2019
1 July 2019
31 December 2019
Quick facts
| Lead sponsor | Shandong Cancer Hospital and Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 15 January 2018 |
| Primary completion | 1 July 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 2 locations across China |
Drugs / interventions tested
- rhGM-CSF — full drug profile →
- Pemetrexed — full drug profile →
- Local Radiotherapy
- Single agent — full drug profile →
Conditions studied
- Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
Sponsor
Shandong Cancer Hospital and Institute
Who can join
Adults 18 to 75, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether chemotherapy combination with local radiotherapy and rhGM-CSF is safe, effective in the treatment of oligometastatic stage IV NSCLC patients.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?
Spaas M, Lievens Y. · · 2019 · cited 31× · PMID 31788476 · DOI 10.3389/fmed.2019.00244 -
Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?
Benna M, Guy JB, Bosacki C, Jmour O, et al · · 2020 · cited 12× · PMID 31971824 · DOI 10.1259/bjr.20190147 -
Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials.
Baydoun A, Lee VL, Biswas T. · · 2022 · cited 11× · PMID 36358757 · DOI 10.3390/cancers14215339 -
Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies.
Leary R, Gardner RB, Mockbee C, Roychowdhury DF. · · 2019 · cited 11× · PMID 31157137 · DOI 10.7759/cureus.4276 -
Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review.
Brandão M, Durieux V, Berghmans T. · · 2021 · cited 4× · PMID 34430381 · DOI 10.21037/tlcr-20-964 -
Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.
Nezamdoust FV, Nezhad-Mokhtari P, Mirzaahmadi B, Mazloumi Z, et al · · 2026 · PMID 42010708 · DOI 10.1186/s13287-026-05011-7
Verify or expand the search:
- PubMed search for NCT03489616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of rhGM-CSF
Trials testing the same drug.
- NCT04072900 — A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma · Phase 1 · unknown
- NCT03113851 — Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer · Phase 2 · completed
- NCT01341652 — Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer · Phase 2 · completed
Other recruiting trials for Carcinoma, Non-Small-Cell Lung
Currently open trials in the same condition.
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
- NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
- NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
- NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
- NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting
Other Shandong Cancer Hospital and Institute trials
Trials by the same sponsor.
- NCT07408505 — Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer · NA · recruiting
- NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
- NCT07376174 — The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T · recruiting
- NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
- NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03489616 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Cancer Hospital and Institute
- Last refreshed: 5 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03489616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing